🚀 VC round data is live in beta, check it out!
CASI Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for CASI Pharmaceuticals and similar public comparables like Pharma Equity Group, Biotechnology Assets, Lexaria Bioscience, Magle Chemoswed Holding and more.
CASI Pharmaceuticals Overview
Founded
N/A
HQ
—
Employees
233
Website
N/A
Sectors
Financials (LTM)
EV
$32M
CASI Pharmaceuticals Financials
CASI Pharmaceuticals reported last 12-month revenue of $11M.
In the same LTM period, CASI Pharmaceuticals generated $4M in gross profit and had net loss of ($38M).
Revenue (LTM)
CASI Pharmaceuticals P&L
In the most recent fiscal year, CASI Pharmaceuticals reported revenue of — and net income of —.
CASI Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $4M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (330%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($38M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (351%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CASI Pharmaceuticals Stock Performance
CASI Pharmaceuticals has current market cap of $17M, and enterprise value of $32M.
CASI Pharmaceuticals' stock price is $0.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $17M | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCASI Pharmaceuticals Valuation Multiples
CASI Pharmaceuticals trades at 3.0x EV/Revenue multiple.
CASI Pharmaceuticals Financial Valuation Multiples
As of March 16, 2026, CASI Pharmaceuticals has market cap of $17M and EV of $32M.
Equity research analysts estimate CASI Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CASI Pharmaceuticals has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17M | XXX | $17M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 8.8x | XXX | — | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CASI Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CASI Pharmaceuticals Margins & Growth Rates
CASI Pharmaceuticals' revenue in the last 12 month declined by (100%).
CASI Pharmaceuticals' revenue per employee in the last FY averaged $0.0M.
CASI Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (53%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 129% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 207% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 60% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CASI Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pharma Equity Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Biotechnology Assets | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexaria Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Magle Chemoswed Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| AcuCort | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CASI Pharmaceuticals M&A Activity
CASI Pharmaceuticals acquired XXX companies to date.
Last acquisition by CASI Pharmaceuticals was on XXXXXXXX, XXXXX. CASI Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CASI Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCASI Pharmaceuticals Investment Activity
CASI Pharmaceuticals invested in XXX companies to date.
CASI Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. CASI Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CASI Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CASI Pharmaceuticals
| How many employees does CASI Pharmaceuticals have? | As of today, CASI Pharmaceuticals has over 233 employees. |
| Is CASI Pharmaceuticals publicly listed? | Yes, CASI Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of CASI Pharmaceuticals? | CASI Pharmaceuticals trades under CASI ticker. |
| When did CASI Pharmaceuticals go public? | CASI Pharmaceuticals went public in 1996. |
| Who are competitors of CASI Pharmaceuticals? | CASI Pharmaceuticals main competitors are Pharma Equity Group, Biotechnology Assets, Lexaria Bioscience, Magle Chemoswed Holding. |
| What is the current market cap of CASI Pharmaceuticals? | CASI Pharmaceuticals' current market cap is $17M. |
| What is the current revenue of CASI Pharmaceuticals? | CASI Pharmaceuticals' last 12 months revenue is $11M. |
| What is the current revenue growth of CASI Pharmaceuticals? | CASI Pharmaceuticals revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of CASI Pharmaceuticals? | Current revenue multiple of CASI Pharmaceuticals is 3.0x. |
| Is CASI Pharmaceuticals profitable? | No, CASI Pharmaceuticals is not profitable. |
| What is the current net income of CASI Pharmaceuticals? | CASI Pharmaceuticals' last 12 months net income is ($38M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.